Skip to main content

Table 4 Cardiovascular risk profile of patients with or without cerebral microbleeds (CMB) according to available MRI data (n = 138)

From: MRI-detected brain lesions in AF patients without further stroke risk factors undergoing ablation - a retrospective analysis of prospective studies

  CMB
  No
(n = 108)
Yes
(n = 30)
p-value*
≥1 stroke risk factor** No 34 (31.5) 5 (16.7) 0.168
Yes 74 (68.5) 25 (83.3)
• Age; median (IQR) 59 (53–65) 64 (56–67) 0.098
Female sex; n (%) 37 (34.3) 4 (13.3) 0.040
Congestive heart failure; n (%) 9 (8.3) 2 (6.7) > 0.999
Arterial hypertension; n (%) 60 (55.6) 18 (60.0) 0.684
Diabetes mellitus; n (%) 9 (8.3) 3 (10.0) 0.769
Peripheral artery occlusive disease; n (%) 1 (0.9) 3 (10.0) 0.032
Coronary artery occlusive Disease; n (%) 18 (16.7) 6 (20.0) 0.786
Hyperlipoproteinemia; n (%) 51 (47.2) 17 (56.7) 0.412
Paroxysmal AF, n (%) 70 (58.8) 19 (59.4) > 0.999
INR > 3.0 prior to ablation, n (%) 16 (14.8) 3 (10.0) 0.765
Intake of phenprocoumon# 93 (86.1) 29 (96.6) 0.194
Intake of NOAK#, *** 15 (13.9) 1 (3.3)
  1. * p-value calculated by chi 2 -test or Mann-Whitney U test, as appropriate. Multivariate analysis was calculated in a binary logistic regression model using backward selection. ** According to CHA 2 DS 2 -VASc-score (“No” equals 0 in men and 1 in women, “Yes” equals ≥ 1 in men and ≥ 2 in women). # at the time of study enrollment. *** Non-Vitamin-K dependent oral anticoagulant